OvaScience (NASDAQ:OVAS) posted its quarterly earnings results on Thursday, March 15th. The biotechnology company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.04, Bloomberg Earnings reports. The business had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.10 million. OvaScience had a negative net margin of 17,338.78% and a negative return on equity of 60.06%.
Shares of OvaScience stock traded down $0.01 on Thursday, reaching $0.88. 85,368 shares of the company traded hands, compared to its average volume of 585,551. OvaScience has a 52-week low of $0.85 and a 52-week high of $2.05. The company has a market capitalization of $31.44, a price-to-earnings ratio of -0.62 and a beta of 3.05.
Several brokerages recently weighed in on OVAS. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of OvaScience in a research report on Friday, March 16th. Zacks Investment Research lowered shares of OvaScience from a “buy” rating to a “hold” rating in a research report on Thursday, January 11th.
COPYRIGHT VIOLATION NOTICE: “OvaScience (OVAS) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/07/ovascience-ovas-posts-earnings-results-beats-expectations-by-0-04-eps.html.
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with MarketBeat.com's FREE daily email newsletter.